Navigation Links
LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
Date:4/30/2008

URES

(amounts in thousands)

(unaudited)

For the three months ended

March 31, 2008 March 31, 2007

Reconciliation between GAAP and Non-

GAAP operating loss:

Operating loss as reported $(2,586) $(977)

Restructuring charges 633 6

Impairment 435 7

Adjusted operating loss $(1,518) $(964)

LEMAITRE VASCULAR, INC (NASDAQ: LMAT)

IMPACT OF FOREIGN CURRENCY AND BUSINESS ACTIVITIES

(unaudited) 2008 2007

(in thousands) Mar Dec Sept June Mar

Total net sales 11,847 11,104 10,144 10,315 9,883

Impact of currency exchange rate

fluctuations (1) 674 439 253 267 322

Net impact of acquisitions,

distributed sales and

discontinued products, excluding

currency exchange rate

fluctuations (2) 1,133 1,116 635 567 455

(unaudited) 2006

(in thousands) Dec Sept June Mar

Total net sales 8,757 8,540 8,760 8,571

Impact of currency exchange rate

fluctuations (1) 232 135 (1) (287)

Net impact of acquisitions,

distributed sales and

discontinued products, excluding

currency exchange rate

fluctuations (2)
'/>"/>

SOURCE LeMaitre Vascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. LeMaitre Vascular to Participate in 28th Annual Cowen and Company Health Care Conference
2. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
3. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
4. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
5. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
6. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
7. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
8. ES Vascular Receives CE Mark for its First Aortic Stapler for End-to-End Anastomosis Between Synthetic Grafts and Aorta During Open Repair of Aortic Aneurysmal and Occlusive Disease
9. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
10. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
11. Boston Scientific Announces Sale of TriVascular Endovascular Aortic Repair Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... METTLER TOLEDO is pleased to announce that the ... PVM technology , is now available. The new ... continuously captures high-resolution images under a wide range ... a report pairing the most relevant images to ... compelling blend of high resolution images and trend ...
(Date:12/15/2014)... COPENHAGEN, Denmark , Dec. 15, 2014 /PRNewswire/ ... its innovative TransCon technology to address significant unmet ... from its ongoing Phase 2 pediatric study to ... growth hormone deficiency, or GHD.  This interim analysis ... the anticipated total enrollment in the study, completing ...
(Date:12/13/2014)... Washington, USA, and TAICHUNG, Taiwan (PRWEB) December 12, 2014 ... rise, despite less rosy indicators in overall global economic ... society for optics and photonics , said in a ... International Conference) on 5 December at the National Chung ... solar energy, which is being integrated into future energy ...
(Date:12/13/2014)... DUBLIN , Dec. 11, 2014 Research ... announced the addition of the "Glucose Sensors: ... http://photos.prnewswire.com/prnh/20130307/600769 ... biocompatible product designs is giving hope for a ... Noninvasive glucose monitors that can measure glucose levels ...
Breaking Biology Technology:New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 2Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 3Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 4Photonics Continues Upward Trends Despite Challenges in the Global Economy, Notes SPIE CEO 5Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3
... create the largest non-state-owned producers of ... plasma-based product in China, ... Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the,"Company"), one ... China ("PRC"), today announced that on September 26,2008, the Company ...
... LIVINGSTON, N.J., Oct. 2 Milestone Scientific,Inc. ... in advanced,injection technologies, today announced that it ... painless anesthetic injections --,specifically rights related to ... providing these injections -- through issuance of ...
... Radioimmunotherapy in U.S. to be Indicated ... for Use in First-Line ... and MTA: CTIC) announced today that it has submitted a ... (FDA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as,consolidation therapy after ...
Cached Biology Technology:China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 2China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 3China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 4China Biologic Products Enters Into Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biologic Technologies Co., Ltd. 5Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations 2Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 2Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 3Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 4Cell Therapeutics Submits Supplemental Biologics License Application for Zevalin Use in First-Line Consolidation Therapy 5
(Date:12/5/2014)... 2014  Tute Genomics, a leader in cloud-based solutions ... A1 funding led by UK-based Eurovestech. Peak Ventures and ... investment round. "We are at a pivotal ... sequencing and seeks new approaches for the diagnosis, treatment ... MD MBA, and CEO of Tute Genomics. "One of ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... New York College, and one of the most prolific ... signals that are transmitted from Smartphones to third party ... Smartphones and has one of the earliest known patents ... its usage in the military, child care, elder care ...
(Date:11/18/2014)... 2014   News Highlights: ... develop The Partners Data Lake, an agile data ... Lake will allow researcher and clinicians to explore ... the lives of patients , The Partners ... across the Partners system, breaking down physical barriers ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... is perhaps impossible to overstate the importance of the tumor ... gene in human tumors. p53 keeps pre-cancerous cells in check ... aging at the cellular level. Loss of p53 causes cells ... or damaged cells die or stop growing. In ...
... This press release is available in Spanish . ... U.S. Department of Agriculture (USDA) scientists are learning more ... fieldsand whether they,ll actively feed on crop pests. ... the North Central Agricultural Research Laboratory in Brookings, S.D., ...
... in sustained tissue damage in the brains and spines of ... reveal. Cytoxic T cells, also known as CD8+ T ... body,s arsenal to fight disease. Multiple sclerosis is characterized ... and destroy the axons, electrical impulse conductors that look like ...
Cached Biology News:Cancer suppressor gene links metabolism with cellular aging 2Cancer suppressor gene links metabolism with cellular aging 3Lady beetle diet influences its effectiveness as biocontrol agent 2Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators 2Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators 3Multiple sclerosis study reveals how killer T cells learn to recognize nerve fiber insulators 4
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated ...
... Ambion's custom siRNA service provides the ... gene silencing research. Custom siRNAs can be ... 19-21 base target sequence, or by providing ... check out Ambion's Silencer Validated and Silencer ...
Human TGF-beta RIIb Affinity Purified Polyclonal Ab...
Biology Products: